

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



# 石四藥集團有限公司 SSY Group Limited

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2005)**

## **VOLUNTARY ANNOUNCEMENT SELECTION RESULTS OF RENEWAL OF NATIONAL CENTRALISED PROCUREMENT**

The board of directors (the “Board”) of SSY Group Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that, on 10 February 2026, a total of 45 products of the Group were selected in the tender results of renewal of the first to the eighth batches of the National Centralised Medicines Procurement (全國藥品集中採購) in China (the “National Centralised Procurement”) covering therapeutic areas such as anti-infection, cardiovascular system, respiratory system, digestive system and nervous system, which is expected to have a positive impact on the Group’s business.

This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.

By order of the Board  
**Chow Hing Yeung**  
*Executive Director and Company Secretary*

Hong Kong, 10 February 2026

*As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Su Xuejun, Mr. Meng Guo, Mr. Chow Hing Yeung and Ms. Qu Wanrong as executive Directors, Mr. Liu Wenjun as non-executive Director, and Mr. Wang Yibing, Mr. Chow Kwok Wai and Mr. Jiang Guangce as independent non-executive Directors.*